Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
Clinical trial NCT05983107 · RECRUITING
Trial details
- NCT number
- NCT05983107
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-20
- Primary completion
- 2026-07-15
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.